Cryopyrin-associated Periodic Syndromes (CAPS) (DBCOND0048690)

Identifiers

Synonyms

Cryopyrin Associated Periodic Syndrome / Cryopyrin-Associated Periodic Syndrome / Cryopyrin-Associated Periodic Syndromes / Cryopyrin associated periodic syndrome (disorder) / Chronic infantile neurological cutaneous and articular syndrome / CINCA syndrome / Chronic infantile neurological, cutaneous and articular syndrome (disorder) / Neonatal-onset multisystemic inflammatory disease / NOMID / Chronic Infantile Neurological, Cutaneous, and Articular Syndrome / Familial Cold Autoinflammatory Syndrome / FCAS / Familial cold urticaria (disorder) / Familial cold urticaria / Muckle-Wells Syndrome / Familial amyloid nephropathy with urticaria AND deafness (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Anakinra	A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).	Interleukin-1 receptor type 1target
Canakinumab	An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).	Interleukin-1 betatarget
Rilonacept	An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder.	Interleukin-1 betatarget Interleukin-1 alphatarget Interleukin-1 receptor antagonist proteintarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04524858	Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)	Zunsemetinib	treatment	2	terminated
NCT05186051	A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)	ZYIL-1	treatment	2	completed
NCT06544018	Circadian Rhythm Deregulation in Patients With CAPS	No drug interventions	other	Not Available	not_yet_recruiting
NCT04856540	Adult Outcomes of Children With CAPS	No drug interventions	Not Available	Not Available	completed
NCT05292768	Are Mast Cells Involved in Autoinflammatory Diseases	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT04086602	Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334	No drug interventions	other	1	completed
NCT01105507	The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada	No drug interventions	treatment	3	completed
NCT05812781	A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome	No drug interventions	treatment	2	completed
NCT02853084	HL2351 CAPS Phase II Study	No drug interventions	treatment	2	terminated
NCT01213641	Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients	No drug interventions	Not Available	Not Available	completed
NCT00685373	Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease	Canakinumab	treatment	3	completed
NCT03923140	A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)	No drug interventions	treatment	2	recruiting
NCT01576367	Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease	No drug interventions	treatment	3	completed
NCT02326376	Kineret CAPS Post Authorisation Study	No drug interventions	Not Available	Not Available	completed
NCT01302860	Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease	No drug interventions	treatment	3	completed
NCT00991146	Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase	No drug interventions	treatment	3	completed